Evidence reviews – January 2020
The following documents contain the evidence that was used to develop the 2020 recommendations:
- Effectiveness of aspirin in the prevention of colorectal cancer in people with Lynch syndrome
- Use of molecular biomarkers to guide systemic therapy
- Treatment for early rectal cancer
- Preoperative radiotherapy and chemoradiotherapy for rectal cancer
- Optimal surgical technique for rectal cancer
- Deferral of surgery in people having neoadjuvant therapy for rectal cancer
- Effectiveness of exenterative surgery for locally advanced or recurrent rectal cancer
- Endoscopic resection alone for early colon cancer
- Preoperative chemotherapy for non-metastatic colon cancer
- Optimal duration of adjuvant chemotherapy for colorectal cancer
- Effectiveness of stenting for acute large bowel obstruction
- Surgery for asymptomatic primary tumour
- Treatment for metastatic colorectal cancer in the liver amenable to treatment with curative intent
- Optimal combination and sequence of treatments in patients presenting with metastatic colorectal cancer in the liver not amenable to treatment with curative intent
- Treatment for metastatic colorectal cancer in the lung amenable to local treatment
- Local and systemic treatments for metastatic colorectal cancer isolated in the peritoneum
- Follow-up to detect recurrence after treatment for non-metastatic colorectal cancer
- Optimal management of low anterior resection syndrome
- Information needs of people prior, during and after treatment for colorectal cancer
- Surgical volumes and outcomes for rectal cancer
This page was last updated: